Patient Capital Sees Royalty Pharma Valuation as Attractive
The strategy cited a 16.7-times multiple of 2027 owners’ earnings and forecast mid-teens earnings growth in most environments.
Makkler Newsroom · Oct 12, 06:38 PM · 1 min read
Royalty Pharma Plc Class A RPRX
NASDAQHealth TechnologyUnited States
$69.31+0.58 (+0.84%)
Market closed· · USD · Data may be delayed
- Day's range
- 68.1469.43
- 52-week range
- 37.3170.37
Financial health
– / 5
Analyst view · 10 firms
Buy8 buy · 2 hold · 0 sell
Avg. target $72.71 (+4.9%)
Prices may be delayed and are for informational purposes only - not investment advice.